In his weekly clinical update, Dr. Griffin discusses guidance on measles during the summer travel season, the Infectious Diseases Society of America guidelines on the diagnosis of COVID-19: antigen testing, SARS-CoV-2 variants and age-dependent infection rates among household and nonhousehold contacts, effect of COVID-19 vaccination on household transmission of SARS-COV-2 in the Omicron era, incidence of myopericarditis after mRNA COVID-19 vaccination, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and Omicron BA.2 variant in Hong Kong, safety, immunogenicity and protection of heterologous boost with an aerosolized Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults, awake prone positioning for non-intubated patients with COVID-19-related acute hypoxic respiratory failure, melatonin effects on sleep quality of COVID-19 patients, female reproductive health impacts of Long COVID and associated illnesses including ME/CFS, POTS, and connective tissue disorders, and incident autoimmune diseases in association with SARS-CoV-2 infection.

In his weekly clinical update, Dr. Griffin discusses the CDC vaccine advisory group recommending the newly approved RSV vaccines, association of culturable-virus detection and household transmission of SARS-CoV-2, prevention of COVID-19 following a single intramuscular administration of Adintrevimab, real-world effectiveness of Nirmatrelvir/Ritonavir on COVID-19, and COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization.

In his weekly clinical update, Dr. Griffin discusses surveillance to track progress toward poliomyelitis eradication, genetic stabilization of attenuated oral vaccines against poliovirus types 1 and 3, evaluation of Oseltamivir used to prevent hospitalization in outpatients with Influenza, viral emissions into the air and environment after SARS-CoV-2 human challenge, has COVID-19 threatened routine childhood vaccination, successful treatment of persistent symptomatic COVID-19 infection with extended duration Nirmatrelvir/Ritonavir, anemia as a risk factor for disease progression in patients admitted for COVID-19, impact of fatigue as the primary determinant of functional limitations among patients with post-COVID-19 syndrome, post-COVID condition in patients with inflammatory rheumatic diseases, outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months, metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, persistent serum protein signatures define an inflammatory subcategory of long COVID, and the relevance of pacing strategies in managing symptoms of post-COVID-19 syndrome.

In his weekly clinical update, Dr. Griffin discusses estimates of SARS-CoV-2 seroprevalence and incidence of primary SARS-CoV-2 infections among blood donors, by COVID-19 vaccination status, smart thermometer–based participatory surveillance to discern the role of children in household viral transmission during the COVID-19 pandemic, COVID-19 vaccine mandates, changing severity and epidemiology of adults hospitalized with COVID-19 in the United States after introduction of COVID-19 vaccines, effectiveness of COVID-19 treatment with Nirmatrelvir–Ritonavir or Molnupiravir among U.S. veterans, national trends in anticoagulation therapy for COVID-19 hospitalized adults in the United States, development of a definition of postacute sequelae of SARS-CoV-2 infection, neuroinflammation after COVID-19 with persistent depressive and cognitive symptoms, long COVID clinical phenotypes up to six months after infection identified by latent class analysis of self-reported symptoms, and coronary microvascular health in symptomatic patients with prior COVID-19 infection.

In his weekly clinical update, Dr. Griffin discusses the potential for recurrent Mpox outbreaks among gay, bisexual, and other men who have sex with men, association between SARS-CoV-2 variants and frequency of acute symptoms, prospective study of key correlates for household transmission of SARS-CoV-2, Pfizer’s PAXLOVID™ receiving FDA approval for adult patients at high risk of progression to severe COVID-19, efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19, development of a definition of postacute sequelae of SARS-CoV-2 infection, COVID-19 and risk for mental disorders among adults in Denmark, risk of new post-COVID mental disorders higher only in older patients.

In his weekly clinical update, Dr. Griffin discusses the CDC HIV surveillance report, FDA voted in favor of approving the Abrysvo vaccine, canine olfactory detection of SARS-CoV-2-infected humans, safety of the BNT162b2 COVID-19 vaccine in children aged 5 to 17 years, and statement on the antigen composition of COVID-19 vaccines.

In his weekly clinical update, Dr. Griffin discusses variant specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on omicron VOC, ventilation in buildings, COVID-19 mortality among selective serotonin reuptake inhibitor users, risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses, trajectories of the evolution of post COVID-19 condition, and efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19.

In his weekly clinical update, Dr. Griffin discusses immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age, influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults, COVID-19 surveillance after expiration of the public health emergency declaration, provisional mortality data, targeted vaccine messaging to promote COVID-19 vaccines for children and youth, vaccines and related biological products advisory committee meeting June 15, 2023 announcement, how to overhaul the CDC, impact of SARS-CoV-2 variants on inpatient clinical outcome, prevalence of post-coronavirus disease condition 12 weeks after Omicron infection compared with negative controls and association with vaccination status, gut bacteria cocktail helps long COVID, and gut microbiota‐derived symbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19.

In his weekly clinical update, Dr. Griffin discusses the U.S. Food and Drug Administration approving Arexvy: the first respiratory syncytial virus (RSV) vaccine approved for use in the United State, association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market, researchers disagree over how bad it is to be reinfected and whether COVID-19 can cause lasting changes to the immune system, virtual care and emergency department use during the COVID-19 pandemic among patients of family physicians in Canada, vaccination with BCG-Denmark did not result in a lower risk of COVID-19 among health care workers than placebo, NVX-CoV2373 vaccine efficacy against hospitalization, comparative effectiveness of the SARS-COV-2 vaccines during Delta dominance, assessment of gender-specific COVID-19 case fatality risk per malignant neoplasm type, clinical outcomes following treatment for COVID-19 with Nirmatrelvir/Ritonavir and Molnupiravir among patients living in nursing homes, timing of intubation and ICU mortality in COVID-19 patients, real-life experience with Remdesivir for treatment of COVID-19 among older adults, and how long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA from the upper respiratory tract during acute infection.